Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in…
Hims & Hers insider transactions Warning as GLP-1 bets grow
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity strategy? Maik Kemper Editor-in-Chief Conclusion…
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the…